Novocure Stock Likely To Slide Further After Delays In Clinical Studies? |
| March 01, 2021 | March 2021 Bond Updates |
|
In late December, we highlighted that the rally in Novocure stock appeared to be overdone. Yesterday, there were multiple developments around the company, including its Q4 results. The company reported revenue of $144 million in Q4, better than the street estimates of $141 million... |
| View more at: https://www.forbes.com/sites/greatspeculations/2021/03/01/novocure-stock-likely-to-slide-further-after-delays-in-clinical-studies/ |
| Related News |
|